Luke A Miles

发表

Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope.

C. Masters, K. Beyreuther, R. Cappai, 2008, Journal of molecular biology.

Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease.

Michael W Parker, Colin L Masters, David B Ascher, 2008, Acta crystallographica. Section F, Structural biology and crystallization communications.

Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β.

Michael W Parker, David B Ascher, M. Parker, 2014, Acta crystallographica. Section F, Structural biology communications.

Structural approaches to probing metal interaction with proteins.

M. Parker, D. Ascher, H. Harris, 2012, Journal of inorganic biochemistry.

Copper binding to the Alzheimer’s disease amyloid precursor protein

R. Cappai, M. Parker, C. Morton, 2007, European Biophysics Journal.

Rates of reactions of H atoms with some CVD precursors

Luke A Miles, Ian A. Cooper, N. L. Arthur, 2000 .

Rate constants for H+(CH3)4−nGeHn, n=1–3

Luke A Miles, N. L. Arthur, 1998 .

Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites

P. Meikle, K. Peter, T. Nero, 2017, Nature Communications.

Promiscuous DNA-binding of a mutant zinc finger protein corrupts the transcriptome and diminishes cell viability.

Michael R. Tallack, R. Sachidanandam, T. Bailey, 2016, Nucleic acids research.

Structures of phage-display peptides that bind to the malarial surface protein, apical membrane antigen 1, and block erythrocyte invasion.

M. Foley, R. Norton, R. Anders, 2003, Biochemistry.

Ex vivo18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

K. Blennow, H. Vanderstichele, H. Zetterberg, 2017, Molecular Neurodegeneration.

Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy.

C. Masters, R. Cappai, D. Tew, 2008, Journal of the American Chemical Society.

Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid beta peptide.

D. Tew, M. Parker, J. Karas, 2009, Chemical communications.

Genomics of Alzheimer’s disease implicates the innate and adaptive immune systems

C. Masters, S. Laws, Luke A Miles, 2021, Cellular and Molecular Life Sciences.

Arrhenius parameters for the reaction of H atoms with SiH4

Luke A Miles, N. L. Arthur, 1997 .

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models

T. Bayer, J. Wiltfang, M. Parker, 2015, Acta Neuropathologica.

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

M. Parker, Luke A Miles, G. Crespi, 2015, Scientific Reports.

Anti-Aβ antibody target engagement: a response to Siemers et al.

David B. Ascher, Victor L. Villemagne, Catriona A. McLean, 2014, Acta Neuropathologica.

Promiscuous DNA-binding of a mutant zinc finger protein corrupts the transcriptome and diminishes cell viability

Michael R. Tallack, R. Sachidanandam, T. Bailey, 2016, Nucleic acids research.

Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Aβ Phagocytosis

T. Nero, M. Parker, M. Rives, 2019, iScience.

Ex vivo18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

K. Blennow, H. Vanderstichele, H. Zetterberg, 2017, Molecular Neurodegeneration.

Novel Therapeutic Approaches to Treat Alzheimer's Disease and Memory Disorders

David B. Ascher, Michael W. Parker, Craig J. Morton, 2008 .

Synthetic dityrosine-linked β-amyloid dimers form stable, soluble, neurotoxic oligomers

R. Cappai, G. Ciccotosto, M. Parker, 2013 .

ERRATUM: Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

M. Parker, Luke A Miles, G. Crespi, 2013, Scientific Reports.

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

M. Parker, Luke A Miles, G. Crespi, 2013, Scientific Reports.

Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?

David B. Ascher, Victor L. Villemagne, Catriona A. McLean, 2014, Acta Neuropathologica.

Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease.

C. Masters, P. Maruff, Yuan Cheng, 2022, Science advances.

Structure of a Novel P-superfamily Spasmodic Conotoxin Reveals an Inhibitory Cystine Knot Motif* 210

R. Norton, M. Hinds, G. Bulaj, 2002, The Journal of Biological Chemistry.

Arrhenius parameters for H+(CH3)4-nSiHn, n=1–3

Luke A Miles, N. L. Arthur, 1998 .

Arrhenius parameters for H+(CH3)3GeH and (CH3)2GeH2

Luke A Miles, Neville L. Arthur, Luke A. Miles, 1998 .

KINETIC ISOTOPE EFFECT FOR THE REACTION OF H ATOMS WITH GEH4 AND GED4

Luke A Miles, Neville L. Arthur, Ian A. Cooper, 1997 .

ERRATUM: Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

M. Parker, Luke A Miles, G. Crespi, 2013, Scientific Reports.

Novel Therapeutic Approaches to Treat Alzheimer's Disease and Memory Disorders

M. Parker, C. Morton, D. Ascher, 2008 .

Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?

M. Parker, V. Villemagne, D. Ascher, 2014, Acta Neuropathologica.

An Escherichia coli cell-free system for recombinant protein synthesis on a milligram scale.

A. Hill, M. Parker, Sen Han, 2011, Methods in molecular biology.

Robust and Cost‐effective Cell‐free Expression of Biopharmaceuticals: Escherichia Coli and Wheat Embryo

Luke A Miles, 2008 .